comparemela.com

Latest Breaking News On - Olve cmnd ca1850532047 - Page 1 : comparemela.com

Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder

Tel Aviv, Israel / Vancouver, Canada, May 22, 2023 Clearmind Medicine Inc. , , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major. | May 22, 2023

New yorkUnited statesTel avivAdi zuloff shaniYale school of medicineFrankfurt stock exchangeCanadian securities exchangeEthics committeeYale school of medicine department psychiatryMedicine incExchange commissionClearmind medicine incMount sinai west icahn school of medicineYale schoolAnahita bassir niaAssistant professor

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Tel Aviv, Israel / Vancouver, Canada, May 19, 2023 Clearmind Medicine Inc. , , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major. | May 19, 2023

Tel avivClearmind medicine incExchange commissionMedicine incFrankfurt stock exchangeNasdaq stock marketCanadian securities exchangeCompany nasdaqNasdaq listing ruleNasdaq capital marketPrivate securities litigation reform actClearmind medicine inc stock exchangePress releaseOlve cmnd ca1850532047

Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial

Tel Aviv, Israel / Vancouver, Canada, April 20, 2023 Clearmind Medicine Inc. , , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major. | April 20, 2023

Tel avivBritish columbiaAdi zuloff shaniCanadian securities exchangeGlobenewswire incExchange commissionClearmind medicine incMedicine incFrankfurt stock exchangeAlcohol use disorderChief executiveStock exchangePrivate securities litigation reform actClearmind medicine inc stock exchangePress releaseOlve cmnd ca1850532047

Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound

Tel Aviv, Israel / Vancouver, Canada, Jan. 31, 2023 Clearmind Medicine Inc. , , a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major. | January 31, 2023

United statesTel avivGal yadidAdi zuloff shaniClearmind medicine incIlan universityFrankfurt stock exchangeExchange commissionTrademark officeMedicine incCanadian securities exchangeGonda multidisciplinary brain research centerBar ilan universityProfessor gal yadidMajor depressive disorderUnited states patent

vimarsana © 2020. All Rights Reserved.